Identification of $ CD8^{+} $ T-cell exhaustion signatures for prognosis in HBV-related hepatocellular carcinoma patients by integrated analysis of single-cell and bulk RNA-sequencing
Background HBV infection is the leading risk factor for HCC. HBV infection has been confirmed to be associated with the exhaustion status of $ CD8^{+} $ T cells and immunotherapeutic efficacy in HCC. In this study, we aimed to investigate the prognostic value of the $ CD8^{+} $ T-cell exhaustion signature and immunotherapy response in patients with HBV-related HCC. Methods We identified different clusters of HBV-related HCC cells by single-cell RNA sequencing (scRNA-seq) and identified $ CD8^{+} $ T-cell exhaustion-related genes (TERGs) by pseudotime analysis. We conducted differential expression analysis and LASSO Cox regression to detect genes and construct a $ CD8^{+} $ T-cell exhaustion index (TEI). We next combined the TEI with other clinicopathological factors to design a prognostic nomogram for HCC patients. We also analysed the difference in the TEI between the non-responder and responder groups during anti-PD-L1 therapy. In addition, we investigated how HBV induces $ CD8^{+} $ T lymphocyte exhaustion through the inhibition of tyrosine metabolism in HCC using gene set enrichment analysis and RT‒qPCR. Results A $ CD8^{+} $ T-cell exhaustion index (TEI) was established with 5 TERGs (EEF1E1, GAGE1, CHORDC1, IKBIP and MAGOH). An AFP level > 500 ng, vascular invasion, histologic grade (G3-G4), advanced TNM stage and poor five-year prognosis were related to a higher TEI score, while HBV infection was related to a lower TEI score. Among those receiving anti-PD-L1 therapy, responders had lower TEIs than non-responders did. The TEI also serves as an independent prognostic factor for HCC, and the nomogram incorporating the TEI, TNM stage, and vascular invasion exhibited excellent predictive value for the prognosis in HCC patients. RT‒qPCR revealed that among the tyrosine metabolism-associated genes, TAT (tyrosine aminotransferase) and HGD (homogentisate 1,2 dioxygenase) were expressed at lower levels in HBV-HCC than in non-HBV HCC. Conclusion Generally, we established a novel TEI model by comprehensively analysing the progression of $ CD8^{+} $ T-cell exhaustion, which shows promise for predicting the clinical prognosis and potential immunotherapeutic efficacy in HBV-related HCC patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
BMC cancer - 24(2024), 1 vom: 10. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Jianhao [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
CD8 |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12885-023-11804-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054340918 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054340918 | ||
| 003 | DE-627 | ||
| 005 | 20240111064650.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240111s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-023-11804-3 |2 doi | |
| 035 | |a (DE-627)SPR054340918 | ||
| 035 | |a (SPR)s12885-023-11804-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Jianhao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Identification of $ CD8^{+} $ T-cell exhaustion signatures for prognosis in HBV-related hepatocellular carcinoma patients by integrated analysis of single-cell and bulk RNA-sequencing |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Background HBV infection is the leading risk factor for HCC. HBV infection has been confirmed to be associated with the exhaustion status of $ CD8^{+} $ T cells and immunotherapeutic efficacy in HCC. In this study, we aimed to investigate the prognostic value of the $ CD8^{+} $ T-cell exhaustion signature and immunotherapy response in patients with HBV-related HCC. Methods We identified different clusters of HBV-related HCC cells by single-cell RNA sequencing (scRNA-seq) and identified $ CD8^{+} $ T-cell exhaustion-related genes (TERGs) by pseudotime analysis. We conducted differential expression analysis and LASSO Cox regression to detect genes and construct a $ CD8^{+} $ T-cell exhaustion index (TEI). We next combined the TEI with other clinicopathological factors to design a prognostic nomogram for HCC patients. We also analysed the difference in the TEI between the non-responder and responder groups during anti-PD-L1 therapy. In addition, we investigated how HBV induces $ CD8^{+} $ T lymphocyte exhaustion through the inhibition of tyrosine metabolism in HCC using gene set enrichment analysis and RT‒qPCR. Results A $ CD8^{+} $ T-cell exhaustion index (TEI) was established with 5 TERGs (EEF1E1, GAGE1, CHORDC1, IKBIP and MAGOH). An AFP level > 500 ng, vascular invasion, histologic grade (G3-G4), advanced TNM stage and poor five-year prognosis were related to a higher TEI score, while HBV infection was related to a lower TEI score. Among those receiving anti-PD-L1 therapy, responders had lower TEIs than non-responders did. The TEI also serves as an independent prognostic factor for HCC, and the nomogram incorporating the TEI, TNM stage, and vascular invasion exhibited excellent predictive value for the prognosis in HCC patients. RT‒qPCR revealed that among the tyrosine metabolism-associated genes, TAT (tyrosine aminotransferase) and HGD (homogentisate 1,2 dioxygenase) were expressed at lower levels in HBV-HCC than in non-HBV HCC. Conclusion Generally, we established a novel TEI model by comprehensively analysing the progression of $ CD8^{+} $ T-cell exhaustion, which shows promise for predicting the clinical prognosis and potential immunotherapeutic efficacy in HBV-related HCC patients. | ||
| 650 | 4 | |a HBV-related hepatocellular carcinoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a CD8 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a T cell exhaustion signatures |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Prognosis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immunotherapy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Chen, Han |4 aut | |
| 700 | 1 | |a Bai, Lang |4 aut | |
| 700 | 1 | |a Tang, Hong |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d London : BioMed Central, 2001 |g 24(2024), 1 vom: 10. Jan. |w (DE-627)SPR027602656 |w (DE-600)2041352-X |x 1471-2407 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:10 |g month:01 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12885-023-11804-3 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 10 |c 01 | ||